Analysis of the Value of Treatment with Terbutaline Combined with Budesonide in Patients with Chronic Obstructive Pulmonary Disease
Objective To analyze the value of treatment with terbutaline combined with budesonide in patients with chronic obstructive pulmonary disease(COPD).Methods The clinical data of 95 cases COPD patients admitted to Linyi Hospital of Traditional Chinese Medicine from February 2022 to December 2023 were retrospectively selected and divided into a control group(n=45)and an observation group(n=50)according to the treatment modality.The con-trol group was treated with salbutamol,and the observation group was treated with terbutaline combined with budesonide,comparing the clinical efficacy,pulmonary function indexes,symptom scores and the occurrence of ad-verse reactions between the two groups.Results The total effective rate of treatment in the observation group was 96.00%,which was higher than of the control group(82.22%),and the difference was statistically significant(χ2=4.774,P<0.05).Before treatment,the two groups'pulmonary function indexes and symptom scores were compared,and the difference was not statistically significant(P>0.05);after treatment,all lung function indexes of the observa-tion group were higher than those of the control group,and all symptom scores were lower than those of the control group,and the differences were statistically significant(both P<0.05).There was no significant difference in the inci-dence of abverse reactions between the two groups(P>0.05).Conclusion Combined treatment with terbutaline and budesonide is more effective in COPD,improves lung function and disease more significantly,and has fewer adverse reactions.
万方数据
维普
